PortalPublikationenImpact of cardiac comorbidities on early and 1-year outcome ...

Impact of cardiac comorbidities on early and 1-year outcome after percutaneous mitral valve interventions: data from the German transcatheter mitral valve interventions (TRAMI) registry

Standard

Impact of cardiac comorbidities on early and 1-year outcome after percutaneous mitral valve interventions: data from the German transcatheter mitral valve interventions (TRAMI) registry. / Schwencke, Carsten; Bijuklic, Klaudija; Ouarrak, Taoufik; Lubos, Edith; Schillinger, Wolfgang; Plicht, Björn; Eggebrecht, Holger; Baldus, Stephan; Schymik, Gerhard; Boekstegers, Peter; Hoffmann, Rainer; Senges, Jochen; Schofer, Joachim.

in: CLIN RES CARDIOL, Jahrgang 106, Nr. 4, 04.2017, S. 249-258.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schwencke, C, Bijuklic, K, Ouarrak, T, Lubos, E, Schillinger, W, Plicht, B, Eggebrecht, H, Baldus, S, Schymik, G, Boekstegers, P, Hoffmann, R, Senges, J & Schofer, J 2017, 'Impact of cardiac comorbidities on early and 1-year outcome after percutaneous mitral valve interventions: data from the German transcatheter mitral valve interventions (TRAMI) registry', CLIN RES CARDIOL, Jg. 106, Nr. 4, S. 249-258. https://doi.org/10.1007/s00392-016-1044-3

APA

Schwencke, C., Bijuklic, K., Ouarrak, T., Lubos, E., Schillinger, W., Plicht, B., Eggebrecht, H., Baldus, S., Schymik, G., Boekstegers, P., Hoffmann, R., Senges, J., & Schofer, J. (2017). Impact of cardiac comorbidities on early and 1-year outcome after percutaneous mitral valve interventions: data from the German transcatheter mitral valve interventions (TRAMI) registry. CLIN RES CARDIOL, 106(4), 249-258. https://doi.org/10.1007/s00392-016-1044-3

Vancouver

Schwencke C, Bijuklic K, Ouarrak T, Lubos E, Schillinger W, Plicht B et al. Impact of cardiac comorbidities on early and 1-year outcome after percutaneous mitral valve interventions: data from the German transcatheter mitral valve interventions (TRAMI) registry. CLIN RES CARDIOL. 2017 Apr;106(4):249-258. https://doi.org/10.1007/s00392-016-1044-3

Bibtex

@article{63c160b1c8144ff0894f3090c963f6aa,
title = "Impact of cardiac comorbidities on early and 1-year outcome after percutaneous mitral valve interventions: data from the German transcatheter mitral valve interventions (TRAMI) registry",
abstract = "AIMS: The use of the MitraClip system has gained widespread acceptance for the treatment of patients with mitral regurgitation (MR) who are not suitable for the conventional surgery. This study sought to investigate the early and 1-year outcome after MitraClip therapy of patients with MR and cardiac comorbidities.METHODS AND RESULTS: Outcomes through 12-month follow-up of patients (n = 528) who underwent MitraClip implantation were obtained from the German transcatheter mitral valve interventions (TRAMI) registry. The majority of these patients (n = 409, 77.5 %) also suffered from coronary artery disease (CAD). Patients with a dilated cardiomyopathy (DCM, n = 65, 12.3 %) or concomitant valvular aortic disease (AV, n = 54, 10.2 %) were less frequent. Although the prevalent pathogenesis was functional MR, patients with DCM had significantly more frequent a functional MR (96.9 %) compared to patients with CAD (74.9 %) or AV (62.5 %, p < 0.001). Technical success was achieved in 97.5 % of patients. Procedural echocardiograms demonstrated in the vast majority of patients a reduction from severe MR III to mild MR I with no difference between the groups (p = 0.83). The peri-procedural complication rate was very low. At 30-day and 12-month follow-up, the majority of patients were in NYHA functional class II or lower. The rate of death, stroke, and myocardial infarction (MACCE) was comparable in the three patient groups during 12-month follow-up (DCM 26.9 %, CAD 30.3 % and AV 27.5 %, p = 0.85).CONCLUSIONS: The MitraClip implantation is feasible and safe even in high-risk patients with MR and cardiac comorbidities.",
keywords = "Aged, Aortic Valve Insufficiency/epidemiology, Cardiac Catheterization/methods, Cardiomyopathy, Dilated/epidemiology, Comorbidity, Coronary Artery Disease/epidemiology, Female, Follow-Up Studies, Germany/epidemiology, Heart Valve Prosthesis, Humans, Male, Mitral Valve Insufficiency/diagnosis, Postoperative Period, Prevalence, Prospective Studies, Prosthesis Design, Registries, Risk Factors, Time Factors",
author = "Carsten Schwencke and Klaudija Bijuklic and Taoufik Ouarrak and Edith Lubos and Wolfgang Schillinger and Bj{\"o}rn Plicht and Holger Eggebrecht and Stephan Baldus and Gerhard Schymik and Peter Boekstegers and Rainer Hoffmann and Jochen Senges and Joachim Schofer",
year = "2017",
month = apr,
doi = "10.1007/s00392-016-1044-3",
language = "English",
volume = "106",
pages = "249--258",
journal = "CLIN RES CARDIOL",
issn = "1861-0684",
publisher = "D. Steinkopff-Verlag",
number = "4",

}

RIS

TY - JOUR

T1 - Impact of cardiac comorbidities on early and 1-year outcome after percutaneous mitral valve interventions: data from the German transcatheter mitral valve interventions (TRAMI) registry

AU - Schwencke, Carsten

AU - Bijuklic, Klaudija

AU - Ouarrak, Taoufik

AU - Lubos, Edith

AU - Schillinger, Wolfgang

AU - Plicht, Björn

AU - Eggebrecht, Holger

AU - Baldus, Stephan

AU - Schymik, Gerhard

AU - Boekstegers, Peter

AU - Hoffmann, Rainer

AU - Senges, Jochen

AU - Schofer, Joachim

PY - 2017/4

Y1 - 2017/4

N2 - AIMS: The use of the MitraClip system has gained widespread acceptance for the treatment of patients with mitral regurgitation (MR) who are not suitable for the conventional surgery. This study sought to investigate the early and 1-year outcome after MitraClip therapy of patients with MR and cardiac comorbidities.METHODS AND RESULTS: Outcomes through 12-month follow-up of patients (n = 528) who underwent MitraClip implantation were obtained from the German transcatheter mitral valve interventions (TRAMI) registry. The majority of these patients (n = 409, 77.5 %) also suffered from coronary artery disease (CAD). Patients with a dilated cardiomyopathy (DCM, n = 65, 12.3 %) or concomitant valvular aortic disease (AV, n = 54, 10.2 %) were less frequent. Although the prevalent pathogenesis was functional MR, patients with DCM had significantly more frequent a functional MR (96.9 %) compared to patients with CAD (74.9 %) or AV (62.5 %, p < 0.001). Technical success was achieved in 97.5 % of patients. Procedural echocardiograms demonstrated in the vast majority of patients a reduction from severe MR III to mild MR I with no difference between the groups (p = 0.83). The peri-procedural complication rate was very low. At 30-day and 12-month follow-up, the majority of patients were in NYHA functional class II or lower. The rate of death, stroke, and myocardial infarction (MACCE) was comparable in the three patient groups during 12-month follow-up (DCM 26.9 %, CAD 30.3 % and AV 27.5 %, p = 0.85).CONCLUSIONS: The MitraClip implantation is feasible and safe even in high-risk patients with MR and cardiac comorbidities.

AB - AIMS: The use of the MitraClip system has gained widespread acceptance for the treatment of patients with mitral regurgitation (MR) who are not suitable for the conventional surgery. This study sought to investigate the early and 1-year outcome after MitraClip therapy of patients with MR and cardiac comorbidities.METHODS AND RESULTS: Outcomes through 12-month follow-up of patients (n = 528) who underwent MitraClip implantation were obtained from the German transcatheter mitral valve interventions (TRAMI) registry. The majority of these patients (n = 409, 77.5 %) also suffered from coronary artery disease (CAD). Patients with a dilated cardiomyopathy (DCM, n = 65, 12.3 %) or concomitant valvular aortic disease (AV, n = 54, 10.2 %) were less frequent. Although the prevalent pathogenesis was functional MR, patients with DCM had significantly more frequent a functional MR (96.9 %) compared to patients with CAD (74.9 %) or AV (62.5 %, p < 0.001). Technical success was achieved in 97.5 % of patients. Procedural echocardiograms demonstrated in the vast majority of patients a reduction from severe MR III to mild MR I with no difference between the groups (p = 0.83). The peri-procedural complication rate was very low. At 30-day and 12-month follow-up, the majority of patients were in NYHA functional class II or lower. The rate of death, stroke, and myocardial infarction (MACCE) was comparable in the three patient groups during 12-month follow-up (DCM 26.9 %, CAD 30.3 % and AV 27.5 %, p = 0.85).CONCLUSIONS: The MitraClip implantation is feasible and safe even in high-risk patients with MR and cardiac comorbidities.

KW - Aged

KW - Aortic Valve Insufficiency/epidemiology

KW - Cardiac Catheterization/methods

KW - Cardiomyopathy, Dilated/epidemiology

KW - Comorbidity

KW - Coronary Artery Disease/epidemiology

KW - Female

KW - Follow-Up Studies

KW - Germany/epidemiology

KW - Heart Valve Prosthesis

KW - Humans

KW - Male

KW - Mitral Valve Insufficiency/diagnosis

KW - Postoperative Period

KW - Prevalence

KW - Prospective Studies

KW - Prosthesis Design

KW - Registries

KW - Risk Factors

KW - Time Factors

U2 - 10.1007/s00392-016-1044-3

DO - 10.1007/s00392-016-1044-3

M3 - SCORING: Journal article

C2 - 27752761

VL - 106

SP - 249

EP - 258

JO - CLIN RES CARDIOL

JF - CLIN RES CARDIOL

SN - 1861-0684

IS - 4

ER -